A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of TGR-1202 and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Trial of the Lymphoma Precision Medicine Laboratory
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Ibrutinib (Primary) ; Umbralisib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 09 Sep 2019 Status changed from active, no longer recruiting to completed.
- 26 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2016 Status changed from not yet recruiting to recruiting.